ALGS Stock Catalyst: Aligos Therapeutics Enters Exclusive License Deal for Pevifoscorvir Sodium in Greater China

Jul 6, 2026 · 4:05pm ET

Received an upfront payment of $25 million.

Max move

+46.0%

High of day $8.60

Sparker timei

4:05pm ET

ALGS · Jul 6, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Aligos Therapeutics, Inc. (Nasdaq: ALGS) has entered into an exclusive license agreement for Pevifoscorvir Sodium in Greater China. The agreement includes an upfront payment of $25 million to Aligos.

The deal grants exclusive rights to the licensee for the development and commercialization of Pevifoscorvir Sodium in the specified region. Aligos will retain rights in other territories.

As of the latest data, Aligos Therapeutics has a free float of 3,640,800 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time ALGS sparks.

Download Sniper App →

Catch the next ALGS-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →